$846 | SAVE $149 | Single User
$1692 | SAVE $298 | Site License
$2121 | SAVE $374 | Global License

Prostate Cancer: Update Bulletin
[Feb 2016]
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2016 | 302 | In Stock
Related Topics: AstraZeneca , Cancer , Prostate Cancer

Introduction

Introduction


Gain new KOL insights on the latest events with the potential to shape the targeted treatment of Prostate Cancer (PC). Topics covered include opinions about the role of custirsen (OGX-011; OncoGenex/Teva) in combination with Jevtana (cabazitaxel; Sanofi) as a second-line treatment for metastatic castrate-resistant PC (mCRPC), and the development of Lynparza (olaparib; AstraZeneca) as a treatment for BRCA1/2 or ATM gene mutated mCRPC in patients who have received prior taxane-based chemotherapy and Zytiga (abiraterone acetate; Johnson & Johnson), or Xtandi (enzalutamide; Astellas/Medivation). The UK’s National Institute for Health and Clinical Excellence’s (NICE) recommendations concerning the use of Xtandi and Zytiga for treating mCRPC in a pre-chemotherapy setting are also discussed.


Key Questions Answered in this Update Bulletin:


  • Do the lacklustre results from the interim analysis of the Phase III AFFINITY trial spell the end for custirsen as a mCRPC therapy?

  • While the TOPARP study confirms Lynparza’s activity in BRCA1/2 and ATM gene mutated mCRPC, how likely is it that the agent will be utilised in a wider prostate cancer patient population?

  • How do KOLs view the recommendations published by the UK’s National Institute for Health and Clinical Excellence (NICE) that Xtandi, but not Zytiga, should be used to treat patients with mCRPC in the pre-chemotherapy setting?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

    Table of Contents
    for Prostate Cancer: Update Bulletin [Feb 2016] [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    302 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 15% today! Global Prostate Cancer Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,271 (normally
    USD $1,495)
    More Info
    SAVE 15% today! Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016
    Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Tria...
    15 Jun 2016 by Global Data USD $2,125 (normally
    USD $2,500)
    More Info
    SAVE 15% today! Vancouver Prostate Centre - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    SummaryVancouver Prostate Centre (Vancouver Prostate) is a cancer research center that conducts rese...
    13 May 2016 by Global Data USD $213 (normally
    USD $251)
    More Info
    SAVE 15% today! Vancouver Prostate Centre - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    SummaryVancouver Prostate Centre (Vancouver Prostate) is a cancer research center that conducts rese...
    17 Mar 2016 by Global Data USD $213 (normally
    USD $251)
    More Info
    SAVE 15% today! Prostate Cancer: KOL Insight
    IntroductionThe last decade has seen significant change in how prostate cancer is treated. Innovatio...
    01 Nov 2015 by FirstWord Pharma USD $6,715 (normally
    USD $7,900)
    More Info
    SAVE 15% today! Physician Views: Can Astellas, Medivation's Xtandi meet expectations in pre-chemotherapy prostate cancer?
    Scope Having secured approval for the treatment of pre-chemotherapy prostate cancer patients earlier...
    25 Sep 2014 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?
    Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget...
    01 Dec 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info
    SAVE 15% today! KOL Insight: Prostate Cancer: Competition intensifies in race to the top
    IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The...
    01 Nov 2013 by FirstWord Pharma USD $6,715 (normally
    USD $7,900)
    More Info
    SAVE 15% today! Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
    IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
    01 Nov 2013 by FirstWord Pharma USD $4,246 (normally
    USD $4,995)
    More Info
    SAVE 15% today! Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?
    ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
    01 Oct 2013 by FirstWord Pharma USD $591 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Prostate Cancer: Update Bulletin [Feb 2016] [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...